Hypersensitivity Reactions to Oxaliplatin in Colorectal Cancer Patients
Author Information
Author(s): Brandi G, Pantaleo M A, Galli C, Falcone A, Antonuzzo A, Mordenti P, Di Marco M C, Biasco G
Primary Institution: Institute of Haematology and Medical Oncology ‘L.& A. Seragnoli’, University of Bologna
Hypothesis
What are the epidemiological and clinical features of hypersensitivity reactions related to oxaliplatin in patients with advanced colorectal cancer?
Conclusion
More than 13% of patients treated with oxaliplatin developed hypersensitivity reactions, which are often not well recognized.
Supporting Evidence
- 17 out of 124 patients reported hypersensitivity reactions attributable to oxaliplatin.
- Symptoms developed after a mean of 9.4 infusions of chemotherapy.
- Patients treated with oxaliplatin alone had a 66.6% reaction rate.
Takeaway
Some people can have bad reactions when they get a medicine called oxaliplatin for cancer, and this happens more often than doctors thought.
Methodology
The study involved 124 outpatients with advanced colorectal cancer treated with oxaliplatin-based therapies from February 1999 to February 2002.
Limitations
The study may not fully capture all hypersensitivity reactions due to the sporadic nature of reports and the relatively recent introduction of oxaliplatin.
Participant Demographics
The mean age of participants was 60.3 years, with 8 males and 9 females experiencing hypersensitivity reactions.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website